Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials

Simple item page
dc.contributor.authorTang, Huilin
dc.contributor.authorZhang, Xi
dc.contributor.authorZhang, Jingjing
dc.contributor.authorLi, Yufeng
dc.contributor.authorDel Gobbo, Liana Christine
dc.contributor.authorZhai, Suodi
dc.contributor.authorSong, Yiqing
dc.contributor.departmentDepartment of Epidemiology, Richard M. Fairbanks School of Public Healthen_US
dc.date.accessioned2017-05-18T16:17:12Z
dc.date.available2017-05-18T16:17:12Z
dc.date.issued2016-12
dc.description.abstractAims/hypothesis By analysing available evidence from randomised controlled trials (RCTs), we aimed to examine whether and to what extent sodium–glucose cotransporter 2 (SGLT2) inhibitors affect serum electrolyte levels in type 2 diabetes patients. Methods We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov up to 24 May 2016 for published RCTs of SGLT2 inhibitors that reported changes in serum electrolyte levels. Weighted mean differences (WMD) between each SGLT2 inhibitor and placebo were calculated using a random-effects model. Dose-dependent relationships for each SGLT2 inhibitor were evaluated using meta-regression analysis. Results Eighteen eligible RCTs, including 15,309 patients and four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin and ipragliflozin) were evaluated. In patients without chronic kidney disease, each SGLT2 inhibitor significantly increased serum magnesium levels compared with placebo (canagliflozin: WMD 0.06 mmol/l for 100 mg and 0.09 mmol/l for 300 mg; dapagliflozin: WMD 0.1 mmol/l for 10 mg; empagliflozin: WMD 0.04 mmol/l for 10 mg and 0.07 mmol/l for 25 mg; and ipragliflozin: WMD 0.05 mmol/l for 50 mg). Canagliflozin increased serum magnesium in a linear dose-dependent manner (p = 0.10). Serum phosphate was significantly increased by dapagliflozin. Serum sodium appeared to significantly differ by SGLT2 inhibitor type. No significant changes in serum calcium and potassium were observed. Findings were robust after including trials involving patients with chronic kidney disease. Conclusions/interpretation SGLT2 inhibitors marginally increased serum magnesium levels in type 2 diabetes patients indicating a drug class effect. Further investigations are required to examine the clinical significance of elevated magnesium levels in individuals with type 2 diabetes.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationTang, H., Zhang, X., Zhang, J., Li, Y., Gobbo, L. C. D., Zhai, S., & Song, Y. (2016). Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia, 59(12), 2546–2551. https://doi.org/10.1007/s00125-016-4101-6en_US
dc.identifier.urihttps://hdl.handle.net/1805/12603
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.isversionof10.1007/s00125-016-4101-6en_US
dc.relation.journalDiabetologiaen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectmeta-analysisen_US
dc.subjectserum electrolytesen_US
dc.subjecttype 2 diabetesen_US
dc.titleElevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trialsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Tang_2016_higher.pdf
Size:
1.51 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Epidemiology Works